Business
Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer
CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) has named David Lebwohl, M.D., as its new executive vice
About this update from Intellia Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., April 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) has named David Lebwohl, M.D., as its new executive vice president and chief medical officer. Dr. Lebwohl brings decades of biopharmaceutial leadership and drug development experience, and joins Intellia to lead its clinical development and regulatory organizations.\n “Dr. Lebwohl joins Intellia during an exciting time for the company, as we continue to rapidly progess our first systemic CRISPR/Cas9-based therapy to the clinic. David’s vast experience in rare diseases, engineered cell therapy and clinical development complement our R&D capabilities and leadership team strength,” said Intellia President and Chief Executive Officer John Leonard, M.D. “He has been at the helm of premier development organizations that launched breakthrough oncology therapies to patients, most notably the recent CAR-T therapy, Kymriah®, and the multi-indication blockbuster, Afinitor®. Under his leadership, we look forward to the impact he can make in delivering Intellia’s CRISPR/Cas9-based treatments to patients.” Dr. Lebwohl’s Professional and Academic Credentials Dr. Lebwohl’s career spans three decades in the biopharmaceutical industry, successfully bringing novel medicines through all phases of clinical trials and global regulatory approvals. During his career, he has overseen multiple full-scale development programs with more than 200 clinical studies across myriad indications. He joins Intellia from Semma Therapeutics, Inc., where he was chief medical officer and led the company’s regenerative medicine efforts using stem-cell-derived pancreatic islets to cure type I diabetes starting in November 2018. Semma was acquired by Vertex Pharmaceuticals Inc., in October 2019. Prior to his role at Semma, Dr. Lebwohl held numerous senior-level drug development leadership positions at the global healthcare company, Novartis Pharmaceuticals Inc. (Novartis), where most recently he was senior vice president and franchise global program head, CAR-T, Promacta and SEG101 Global Program Teams, responsible for the development of the breakthrough therapy Kymriah® (tisagenlecleucel), approved for the treatment of B-cell acute lymphoblastic leukemia. Dr. Lebwohl also was responsible for numerous other Novartis oncology drug development programs, and led the company’s Cell ...